Moderna faces a slew of challenges in keeping with its bigger competitors in the chase for a COVID-19 vaccine, most crucially its limited manufacturing and distribution capacity. With its supply chain on the upswing, Moderna is looking to nab an expansive distribution deal with the EU as a complement to its multibillion-dollar U.S. pact.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,